Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes

NCT03668470 on ClinicalTrials.gov · last registry update 2021-07-08

A small phase 2 — 45 participants, against a typical 110. The sponsor logged completion for 3 February 2021. Primary outcome, as filed: HbA1c level.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Hospices Civils de Lyon
Sponsor type: Other
Enrollment: 45
Started: 2019-01-31
Primary completion: 2021-02-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c level

Conditions studied

Adult Subjects With Type1Diabetes and Insulin Microsecretion

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.